FDA Imposes Very Strict Guidelines on HCQ, Chloroquine, and AZM


Health Editor’s Note: Read this FDA communication listing restrictions for the use of hyroxychloroquine, chloroquine, and azithromycin. The use of these medications may cause irregularities in the electrical system of the heart and create a situation where the left ventricle of the heart beats too fast (ventricular tachycardia) and thus decreases the effectiveness of the heart to pump blood from the heart to the rest of the body. This can be a lethal condition….Carol 

FDA Drug Safety Communication

FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems

Close supervision is strongly recommended

The FDA is aware of reports of serious heart rhythm problems in patients with COVID-19 treated with hydroxychloroquine or chloroquine, often in combination with azithromycin and other QT prolonging medicines.

We are also aware of increased use of these medicines through outpatient prescriptions. Therefore, we would like to remind health care professionals and patients of the known risks associated with both hydroxychloroquine and chloroquine. FDA will continue to investigate risks associated with the use of hydroxychloroquine and chloroquine
for COVID-19 and communicate publicly when we have more information.

Hydroxychloroquine and chloroquine have not been shown to be safe and effective for treating or preventing COVID-19. They are being studied in clinical trials for COVID-19, and we authorized their temporary use during the COVID-19 pandemic for treatment of the virus in hospitalized patients when clinical trials are not available, or participation is not feasible, through an Emergency Use Authorization (EUA). The medicines being used under the hydroxychloroquine/chloroquine EUA are supplied from the Strategic National Stockpile, the national repository of critical medical supplies to be used during public health emergencies. This safety communication reminds physicians and the public of risk information set out in the hydroxychloroquine and chloroquine healthcare provider
fact sheets that were required by the EUA.

Hydroxychloroquine and chloroquine can cause abnormal heart rhythms such as QT interval prolongation and a dangerously rapid heart rate called ventricular tachycardia. These risks may increase when these medicines are combined with other medicines known to prolong the QT interval, including the antibiotic azithromycin, which is also being used in some COVID-19 patients without FDA approval for this condition. Patients who also have other
health issues such as heart and kidney disease are likely to be at increased risk of these heart problems when receiving these medicines.

Read More:

Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy


  1. This puzzles me.

    I thought that this was a well proven drug, used for decades on lupus and malaria, with side effects that are well known already to the medical profession.

Comments are closed.